Genmab — November 2018

[Parasitism]

Så kom det også på NN

[Thomas]

Wow ADCT 301 lyder super stærkt?

[henrik48]

Jeg må desværre have min onkolog-datter til at fortolke alle de informationer...lol

[henrik48]

Men det lyder altsammen lovende

[Bulder]

Ja i cHL. I NHL er responsraterne ikke så høje. https://ash.confex.com/ash/2018/webprogram/Paper115986.html

[Bulder]

henrik48: Spørg lige din datter om cHL er nemmere at behandle end NHL.

[Bulder]

Helge, er du på?

[henrik48]

@bulder - nu er hun neuroonkolog og ikke ekspert i blod...men jeg skal forsøge

[gentogen]

This is the first report of the use of daratumumab in LCDD. This antibody yielded rapid and significant hematologic responses in five of six heavily pretreated patients with this disease, preventing renal progression. Daratumumab represents a promising option for these patients and larger, international studies are warranted.

[Thomas]

A compound within a compound...

[Thomas]

Eller var det a pipeline within a compound. Either way...

[gentogen]

D-VMP provides a consistent and statistically significant PFS benefit relative to Rd continuous, Rd 18, and MPT

[gentogen]

Webprogram Unavailable

(ash.confex.com)

[Bulder]

Ja, gentogen, det betyder jo at Alcyone vil gå sin sejrsgang i row.

[Bulder]

... hvis landene vil betale merprisen for dara.

[gentogen]

CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. These data support the further development of this combination as a convenient, cost effective alternative to PI-IMiD-DARA based combinations

[Bulder]

Ja, men det er det lille irske studie. Konklusionen i det større Lyra er ikke så overvældende.

[Helge_LarsenPI-redaktør]

Det er jeg Bulder.

[Bulder]

Ok, har skrevet en besked i stedet

[Budweis]

Markedet tager da pænt imod Genmabs abstract fyrværkeri